.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,119,061

« Back to Dashboard

Claims for Patent: 7,119,061

Title:Dalbavancin compositions for treatment of bacterial infections
Abstract: The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of dalbavancin formulations for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimes include once weekly administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection.
Inventor(s): Stogniew; Martin (Blue Bell, PA)
Assignee: Vicuron Pharmaceuticals, Inc. (King of Prussia, PA)
Application Number:10/834,395
Patent Claims: 1. A dry formulation comprising: dalbavancin; at least one stabilizer that is a sugar; wherein the formulation has a pH of about 4 5; wherein the formulation contains no more than about 5% MAG by weight after about three months at 40.degree. C.

2. The formulation of claim 1, wherein the sugar is selected from mannitol, lactose, sucrose, sorbitol, glycerol, cellulose, trehalose, maltose, or dextrose.

3. The formulation of claim 1, wherein the ratio of dalbavancin to stabilizer is about 2:1 by weight.

4. The formulation of claim 1, wherein formulation is freeze-dried.

5. The formulation of claim 1, wherein the sugar comprises lactose or mannitol.

6. The formulation of claim 1, wherein the sugar comprises lactose or mannitol and the ratio of dalbavancin to stabilizer is about 2:1 by weight.

7. The formulation of claim 1, wherein the sugar comprises mannitol or lactose, and further comprising a second stabilizer comprising a second sugar.

8. The formulation of claim 1, wherein the sugar comprises mannitol, and further comprising a second stabilizer comprising lactose.

9. The formulation of claim 1, wherein the sugar comprises mannitol, and further comprising a second stabilizer comprising lactose, and wherein the ratio of dalbavancin to mannitol to lactose is about 4:1:1 by weight.

10. A dry formulation comprising: dalbavancin; a stabilizer comprising lactose and mannitol; wherein the formulation pH is about 4.5; wherein the formulation contains no more than about 4% MAG by weight after about three months at 40.degree. C.; and wherein the formulation is freeze-dried.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc